Alzamend Neuro Receives Nasdaq Non-Compliance Notice for Equity Deficiency
ALZN sits 16% above its 52-week low of $1.58.
Summary
Alzamend Neuro received a Nasdaq notice for failing to meet the minimum $2.5 million stockholders' equity requirement, initiating a compliance period to avoid potential delisting.
Key Events · Corporate Governance and Compliance · ALZN
-
Nasdaq Non-Compliance Notice Received
Alzamend Neuro received a letter from Nasdaq on March 20, 2026, indicating non-compliance with the minimum stockholders' equity requirement.
-
Equity Below Listing Standard
The company's stockholders' equity was approximately $2.2 million as of January 31, 2026, falling below Nasdaq's Rule 5550(b)(1) minimum of $2.5 million.
-
Compliance Plan Required
Alzamend Neuro has 45 calendar days, until May 4, 2026, to submit a plan to regain compliance. If accepted, Nasdaq may grant up to 180 days (until September 16, 2026) to demonstrate compliance.
-
Potential Delisting Risk
Failure to regain compliance could lead to delisting from The Nasdaq Capital Market, though the company retains the right to appeal such a decision.
Analysis · ALZN · Life Sciences
Alzamend Neuro, a nano-cap biotech, has received a critical notice from Nasdaq for failing to meet the minimum stockholders' equity requirement. This is a significant event as continued listing on Nasdaq is crucial for liquidity and investor confidence, especially for a company in the clinical trial stage. The company's reported equity of $2.2 million falls short of the $2.5 million threshold, indicating financial fragility. While there is a compliance period, the need to raise additional equity adds pressure, particularly following the recent establishment of a $3 million At-The-Market (ATM) offering on March 6, 2026. The success of this ATM program or other capital-raising efforts will be vital for the company to regain compliance and avoid potential delisting.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 42% of the 419 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.47%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALZN was trading at $1.83 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7M. The 52-week trading range was $1.58 to $10.17. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.